NASDAQ:ACRX

AcelRx Pharmaceuticals (ACRX) Stock Forecast, Price & News

$1.03

-0.06 (-5.50%)

(As of 05:11 PM ET)

Compare

Today's Range: $1.03
▼
$1.14
50-Day Range: $0.60
▼
$1.11
52-Week Range: $0.55
▼
$7.60

Volume: 33,520 shs
Average Volume: 194,367 shs
Market Capitalization: $11.25 million

P/E Ratio: 0.15
Dividend Yield: N/A
Price Target: N/A

AcelRx Pharmaceuticals MarketRank™ Forecast

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
7.08% of Float Sold Short
Dividend Strength: N/A
Sustainability: -2.41
Upright™ Environmental Score
News Sentiment: 0.58
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.67) to ($2.00) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.03 out of 5 stars

Medical Sector

436th out of 983 stocks

Pharmaceutical Preparations Industry

210th out of 486 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for AcelRx Pharmaceuticals.

4.0

Short Interest

Percentage of Shares Shorted
7.08% of the float of AcelRx Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
AcelRx Pharmaceuticals has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in AcelRx Pharmaceuticals has recently decreased by 10.52%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
AcelRx Pharmaceuticals does not currently pay a dividend.
Dividend Growth
AcelRx Pharmaceuticals does not have a long track record of dividend growth.

3.9

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
AcelRx Pharmaceuticals has received a 53.29% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Sufentanil" and "Clinical research services for physiological diseases " products. See details.
Environmental Sustainability
The Environmental Impact score for AcelRx Pharmaceuticals is -2.41.

2.5

News and Social Media Coverage

News Sentiment
AcelRx Pharmaceuticals has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for AcelRx Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
10 people have searched for ACRX on MarketBeat in the last 30 days. This is an increase of 11% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, AcelRx Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.60% of the stock of AcelRx Pharmaceuticals is held by insiders.

1.9

Earnings and Valuation

Earnings Growth
Earnings for AcelRx Pharmaceuticals are expected to decrease in the coming year, from ($1.67) to ($2.00) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of AcelRx Pharmaceuticals is 0.15, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 125.68.
Price to Earnings Ratio vs. Sector
The P/E ratio of AcelRx Pharmaceuticals is 0.15, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 97.39.
Price to Book Value per Share Ratio
AcelRx Pharmaceuticals has a P/B Ratio of 0.82. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About AcelRx Pharmaceuticals (NASDAQ:ACRX) Stock

AcelRx Pharmaceuticals, Inc. engages in the development and commercialization of therapies use in medically supervised settings. The firm's portfolio includes DSUVIA, DZUVEO, Zalviso, ARX-02 and ARX-03. The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in Hayward, CA.

Receive ACRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AcelRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ACRX Stock News Headlines

May 31, 2023 | americanbankingnews.com

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Short Interest Update

May 30, 2023 | americanbankingnews.com

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Sees Significant Drop in Short Interest

June 2, 2023 | Edge On The Street (Ad)

The Real Problem With "Made in America" Lithium

Politicians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple.

May 17, 2023 | americanbankingnews.com

AcelRx Pharmaceuticals, Inc. to Post Q2 2023 Earnings of ($0.53) Per Share, HC Wainwright Forecasts (NASDAQ:ACRX)

May 13, 2023 | finanznachrichten.de

AcelRx Pharmaceuticals, Inc.: AcelRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 12, 2023 | americanbankingnews.com

AcelRx Pharmaceuticals (NASDAQ:ACRX) Rating Lowered to Sell at StockNews.com

May 11, 2023 | msn.com

Recap: AcelRx Pharmaceuticals Q1 Earnings

May 10, 2023 | finance.yahoo.com

AcelRx Pharmaceuticals (ACRX) Reports Break-Even Earnings for Q1

June 2, 2023 | Edge On The Street (Ad)

The Real Problem With "Made in America" Lithium

Politicians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple.

May 10, 2023 | finance.yahoo.com

AcelRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 8, 2023 | americanbankingnews.com

AcelRx Pharmaceuticals (ACRX) to Release Earnings on Wednesday

May 4, 2023 | finance.yahoo.com

Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q1 Earnings Expected to Decline

May 3, 2023 | msn.com

AcelRx Pharmaceuticals (ACRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

April 27, 2023 | finance.yahoo.com

AcelRx to Host First Quarter 2023 Financial Results Call and Webcast on May 10, 2023

April 19, 2023 | americanbankingnews.com

Short Interest in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Expands By 17.5%

April 8, 2023 | americanbankingnews.com

AcelRx Pharmaceuticals (NASDAQ:ACRX) Upgraded by StockNews.com to Hold

April 5, 2023 | finance.yahoo.com

AcelRx Pharmaceuticals Announces Closing of Divestment of DSUVIA® to Alora Pharmaceuticals

April 4, 2023 | finance.yahoo.com

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q4 2022 Earnings Call Transcript

March 31, 2023 | finanznachrichten.de

AcelRx Pharmaceuticals, Inc.: AcelRx Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results and Provides Corporate Update

March 31, 2023 | markets.businessinsider.com

Acelrx (ACRX) Receives a Hold from H.C. Wainwright

March 30, 2023 | finance.yahoo.com

AcelRx Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results and Provides Corporate Update

March 29, 2023 | msn.com

Earnings Outlook For AcelRx Pharmaceuticals

March 29, 2023 | americanbankingnews.com

AcelRx Pharmaceuticals (ACRX) Set to Announce Earnings on Thursday

March 21, 2023 | finance.yahoo.com

AcelRx to Host Full Year and Fourth Quarter 2022 Financial Results Call and Webcast on March 30, 2023

March 14, 2023 | marketwatch.com

AcelRx Pharmaceuticals Shares Rise Premarket on Dsuvia Sale >ACRX

March 14, 2023 | msn.com

AcelRx adds 16% on plans to divest pain therapy

March 14, 2023 | finance.yahoo.com

AcelRx Pharmaceuticals Announces Divestment of DSUVIA® to Alora Pharmaceuticals

See More Headlines

ACRX Price History

30 days | 90 days | 365 days | Advanced Chart

ACRX Company Calendar

Last Earnings: 3/30/2023
Today: 6/02/2023
Next Earnings (Estimated): 8/10/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ACRX
CUSIP: N/A
CIK: 1427925
Web: www.acelrx.com
Phone: (650) 216-3500
Fax: 650-216-6500
Employees: 43
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): $6.91
Trailing P/E Ratio: 0.16
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $47.76 million
Net Margins: 2,696.50%
Pretax Margin: 3,946.35%
Return on Equity: -93.99%
Return on Assets: -50.85%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.83
Quick Ratio: 1.83

Sales & Book Value

Annual Sales: $1.77 million
Price / Sales: 6.72
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.30 per share
Price / Book: 0.84

Miscellaneous

Outstanding Shares: 10,920,000
Free Float: 10,312,000
Market Cap: $11.90 million
Optionable: Optionable
Beta: 0.25

Key Executives

Vincent J. Angotti
President, Chief Executive Officer & Director

Raffi Asadorian
Chief Financial & Accounting Officer

Pamela Pierce Palmer
Director & Chief Medical Officer

Badri N. Dasu
Chief Engineering Officer

Mark A. Evashenk
Vice President-Clinical Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ACRX Stock - Frequently Asked Questions

How have ACRX shares performed in 2023?: AcelRx Pharmaceuticals' stock was trading at $2.26 at the beginning of 2023. Since then, ACRX stock has decreased by 51.8% and is now trading at $1.09.
View the best growth stocks for 2023 here.
Are investors shorting AcelRx Pharmaceuticals?: AcelRx Pharmaceuticals saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 765,800 shares, a drop of 10.5% from the April 30th total of 855,800 shares. Based on an average trading volume of 204,900 shares, the days-to-cover ratio is currently 3.7 days. Approximately 7.1% of the company's shares are sold short.
View AcelRx Pharmaceuticals' Short Interest.
When is AcelRx Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our ACRX earnings forecast.
How were AcelRx Pharmaceuticals' earnings last quarter?: AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) posted its quarterly earnings data on Thursday, March, 30th. The specialty pharmaceutical company reported ($1.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by $0.90. AcelRx Pharmaceuticals had a net margin of 2,696.50% and a negative trailing twelve-month return on equity of 93.99%.
When did AcelRx Pharmaceuticals' stock split?: AcelRx Pharmaceuticals's stock reverse split on Wednesday, October 26th 2022. The 1-20 reverse split was announced on Wednesday, October 26th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, October 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.
What other stocks do shareholders of AcelRx Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other AcelRx Pharmaceuticals investors own include Advanced Micro Devices (AMD), Novavax (NVAX), Amarin (AMRN), Amicus Therapeutics (fold), Inovio Pharmaceuticals (INO), TG Therapeutics (TGTX), OPKO Health (OPK), CyberArk Software (CYBR), Flexion Therapeutics (FLXN) and NVIDIA (NVDA).

What is AcelRx Pharmaceuticals' stock symbol?: AcelRx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACRX."
Who are AcelRx Pharmaceuticals' major shareholders?: AcelRx Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (0.37%), Simplex Trading LLC (0.00%) and Group One Trading L.P. (0.00%). Insiders that own company stock include Adrian Adams and Vincent J Angotti.
View institutional ownership trends.
How do I buy shares of AcelRx Pharmaceuticals?: Shares of ACRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is AcelRx Pharmaceuticals' stock price today?: One share of ACRX stock can currently be purchased for approximately $1.09.
How much money does AcelRx Pharmaceuticals make?: AcelRx Pharmaceuticals (NASDAQ:ACRX) has a market capitalization of $11.90 million and generates $1.77 million in revenue each year. The specialty pharmaceutical company earns $47.76 million in net income (profit) each year or $6.91 on an earnings per share basis.
How can I contact AcelRx Pharmaceuticals?: AcelRx Pharmaceuticals' mailing address is 351 GALVESTON DRIVE, REDWOOD CITY CA, 94063. The official website for the company is www.acelrx.com. The specialty pharmaceutical company can be reached via phone at (650) 216-3500, via email at bkorb@troutgroup.com, or via fax at 650-216-6500.

This page (NASDAQ:ACRX) was last updated on 6/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial